VRCA · Verrica Pharmaceuticals Inc
United States · RS rating 13 · As of 2026-11-03
| Price | 3.29 USD |
|---|---|
| 1-day change | +2.5% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 18 / 13 / 44 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 6 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +21.1% |
| Sales growth Q/Q | -64.5% |
| Distance from 52-week high | +63.9% |
| Market cap (USD) | $111.5M |